Univest
Univest
  • Markets

AVIENCE BIOMEDICALS LTD Hits Upper Circuit on NSE, 27 October 2026

  • September 28, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
AVIENCE BIOMEDICALS upper circuit today on NSE

A move in one stock says little until it is set beside others in the same field, and the AVIENCE BIOMEDICALS upper circuit on 27 October 2026 is a case in point. AVIENCE BIOMEDICALS LTD (AVIENCE) hit the limit on NSE at Rs 264.6, a 5% rise from the previous close of Rs 252, and the stock was still locked there at the time of writing. The company’s market cap stood at Rs 138.22 crore.

Table of Contents

Toggle
  • Key Takeaways
  • Key Market Data
  • Price Action and Trading Activity
  • Why AVIENCE BIOMEDICALS LTD Hit Upper Circuit
  • What the AVIENCE BIOMEDICALS Upper Circuit Means
  • AVIENCE BIOMEDICALS LTD Fundamentals and Valuation
  • Peer and Sector Context
  • Technical Snapshot
  • What Readers Should Know
  • Frequently Asked Questions
    • Why did AVIENCE BIOMEDICALS LTD hit upper circuit on 27 October 2026?
    • What was AVIENCE share price on 27 October 2026?
    • What was the upper circuit price for AVIENCE?
    • What is AVIENCE BIOMEDICALS LTD’s market cap and PE ratio?
    • Which exchange and data source were used?
    • Does hitting an upper circuit mean AVIENCE BIOMEDICALS LTD is a buy or a sell?
    • Can you buy or sell AVIENCE BIOMEDICALS LTD shares when the stock is at the upper circuit?
    • What happens the next trading session after an upper circuit?
    • What is the upper circuit limit set at for Indian stocks?

Key Takeaways

  • AVIENCE BIOMEDICALS LTD (AVIENCE) hit the upper circuit on NSE at Rs 264.6 on 27 October 2026.
  • The session move was +5% against a previous close of Rs 252.
  • Market capitalisation stood at Rs 138.22 crore with a PE ratio of 15.79.
  • No official company announcement or verified catalyst was confirmed at the time of writing.
  • A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

Metric Value
Stock AVIENCE BIOMEDICALS LTD
Current Price / LTP Rs 264.6
Day Move 5%
Previous Close Rs 252
Day Open Rs 252
Day High Rs 264.6
Day Low Rs 252
Upper Circuit Price Rs 264.6
Upper Circuit Limit Rs 264.6
Market Cap Rs 138.22 crore
Selected Exchange NSE
PE Ratio 15.79

All figures above are as of 27 October 2026, sourced from Univest market data for the NSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

The stock opened at Rs 252 on NSE, exactly level with the previous close of Rs 252, and that price was also the low for the day. From there it moved straight up to Rs 264.6, the band limit, without trading below its opening level.

The gain was Rs 12.6, which is the 5% move in rupee terms. All figures are NSE figures, since band limits and previous-close values may differ on another exchange.

The range therefore ran from Rs 252 to the ceiling, with the stock holding its opening price throughout.

Why AVIENCE BIOMEDICALS LTD Hit Upper Circuit

Buyers carried the price from the flat open to the exchange band, which is how an upper circuit forms. No official company announcement or verified external catalyst had been confirmed at the time of writing, so the move is best read through price action and market sentiment.

As no trigger was confirmed, the article does not tie the rise to earnings, a corporate action, sector news or market rumours. A confirmed announcement, if one arrives later, would be added in a separate update.

The level reached was Rs 264.6.

What the AVIENCE BIOMEDICALS Upper Circuit Means

The company sits in the Healthcare sector, under medical equipment, supplies and accessories. A sector label helps place the name, but a band hit by one stock is not evidence of a wider move among similar companies. The ceiling for AVIENCE BIOMEDICALS LTD was Rs 264.6 on 27 October 2026.

Bands exist to slow sharp swings and keep trading orderly. They describe how the market is built and offer no forecast of returns. The circuit only marks where the price was held.

AVIENCE BIOMEDICALS LTD Fundamentals and Valuation

The reported data for AVIENCE BIOMEDICALS LTD show a PE ratio of 15.79, a PB ratio of 5.7, book value of Rs 44.18 and EPS of 15.96, against a market cap of Rs 138.22 crore. They are reference indicators and not a buy, sell or hold view.

A PB ratio of 5.7 means the market priced the company at a multiple of its reported book value per share. Growth hopes, asset quality or thin trading in a smaller counter could each account for a premium like that.

Peer ratios would be needed to judge whether these readings are high or low for the field, and none are used here. One sharp day draws notice, but valuation and returns on capital need their own review, apart from the price event.

Peer and Sector Context

AVIENCE BIOMEDICALS LTD belongs to the Medical Equipment/Supplies/Accessories industry within the Healthcare sector. The peer table below uses available companies from the same sector or industry to give broader valuation context.

Peer Company Market Cap PE PB ROE
Q-LINE BIOTECH LIMITED Rs 1263.46 crore 22.67 4.99 25.55%
3B Blackbio Dx Ltd. Rs 1195.09 crore 21.52 3.58 20.22%
LAXMI DENTAL LIMITED Rs 943.75 crore 30.55 3.85 11.95%
Hemant Surgical Industries Ltd. Rs 825.15 crore 45.36 5.73 12.73%
Osel Devices Ltd. Rs 598.25 crore 20.48 2.99 18.97%

Several of these peers are far larger by market capitalisation than AVIENCE BIOMEDICALS LTD. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.

AVIENCE BIOMEDICALS LTD’s PE ratio was 15.79, compared with an available peer PE average of 28.12, calculated from the 5 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Want to know more? Log in to Univest for more stock insights.

Technical Snapshot

Technical indicators were limited in the latest market dataset, so this article does not draw a technical conclusion beyond the confirmed upper circuit event.

What Readers Should Know

The confirmed facts are limited: AVIENCE BIOMEDICALS LTD touched the upper circuit on NSE at Rs 264.6 on 27 October 2026, a 5% move on the day.

Execution is the practical hurdle. Bids queue at the band while sellers stay away, so the quoted price may not be one at which shares can really be bought. No official catalyst had been confirmed when this was written either.

This is a market update and not a conclusion about the business. Strong interest at the band still leaves fundamentals, valuation, liquidity, risk and company disclosures to be checked.

Frequently Asked Questions

Why did AVIENCE BIOMEDICALS LTD hit upper circuit on 27 October 2026?

The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

What was AVIENCE share price on 27 October 2026?

The last traded price used in this article was Rs 264.6 on NSE. That price matched the upper circuit price captured for the event.

What was the upper circuit price for AVIENCE?

The upper circuit price was Rs 264.6. The stated exchange upper circuit limit was Rs 264.6. The event numbers in this article are aligned to NSE.

What is AVIENCE BIOMEDICALS LTD’s market cap and PE ratio?

AVIENCE BIOMEDICALS LTD’s market cap was Rs 138.22 crore. PE ratio was 15.79.

Which exchange and data source were used?

The selected exchange was NSE. The article uses Univest market data available at the time of generation, captured on 27 October 2026.

Does hitting an upper circuit mean AVIENCE BIOMEDICALS LTD is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell AVIENCE BIOMEDICALS LTD shares when the stock is at the upper circuit?

It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.

What happens the next trading session after an upper circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the upper circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For AVIENCE BIOMEDICALS LTD the stated limit was Rs 264.6. For this session, AVIENCE BIOMEDICALS LTD moved 5%.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply